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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron degenerative disease
that has no effective treatment up to date. Drug discovery tasks have been hampered due
to the lack of knowledge in its molecular etiology together with the limited animal models for
research. Recently, a motor neuron disease animal model has been developed using β-N-
methylamino-L-alanine (L-BMAA), a neurotoxic amino acid related to the appearing of ALS.
In the present work, the neuroprotective role of VP2.51, a small heterocyclic GSK-3 inhibi-
tor, is analysed in this novel murinemodel together with the analysis of autophagy. VP2.51
daily administration for two weeks, starting the first day after L-BMAA treatment, leads to
total recovery of neurological symptoms and prevents the activation of autophagic pro-
cesses in rats. These results show that the L-BMAAmurinemodel can be used to test the
efficacy of new drugs. In addition, the results confirm the therapeutic potential of GSK-3
inhibitors, and specially VP2.51, for the disease-modifying future treatment of motor neuron
disorders like ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects
nerve cells in brain and in the spinal cord. It is the most commonmotor neuron disease in
adults, and causes progressive impairment of voluntary muscles involved in movement, respi-
ration, speech, and swallowing. The progressive neuromuscular failure is invariably lethal
within a few years after the onset of symptoms with some exceptions. The disease is divided in
familial ALS (fALS), the hereditary form, that occurs only in 5%-10% of cases, and sporadic
ALS (sALS), that accounts for the majority of the reported cases [1]. The economic and social
burden of the disease is substantial [2], [3], and no effective treatment is currently available [4].
Recent findings in ALS molecularmechanisms could accelerate the discovery of an effective
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pharmacological intervention for this disease [5], and new therapeutic approaches are being
explored uninterruptedly [6]. However, preclinical models used are based on the familial ALS
mutation of superoxide dismutase SOD1 G93A, which represent a minority of the affected
patients, and the use of an unrepresentative model could be the cause of drug failures in the
clinic. Thus, there is an urgent need to find better models for this devastating disease.
In the last years, the neurotoxin β-N-methylamino-L-alanine (L-BMAA) has been proposed
as one of the causes for the occurrence of sALS [7]. L-BMAA reached a great interest by its
involvement in the origin of several neurodegenerative diseases [8] and its use in the search for
sporadic animal models that emulate these pathologies [9]. This is of special importance for
sALS where no established experimentalmodels are currently available. Therefore, although
there are many previous studies regarding L-BMAA toxicity [10], and adequate diseasemodel
for testing potential drugs has not achieved yet, and the SOD1 G93A transgenic mouse that
mimic some fALS, representing minority of ALS cases, is the only ALS murine model used in
drug discovery [11]. In previous work we have reported an experimentalmodel of motor neu-
ron disease in rats by their treatment with L-BMAA [12], [13], [14], that would allow not only
for the study of the pathological neurodegenerativemechanism but also for the discovery of
effective drugs that stop or delay the progression of this fatal disease.
In that model, animals treated with L-BMAA display a neurological impairment compatible
with sALS symptoms. L-BMAA treatment starts at day 21 after birth and it is administered for
5 consecutive days. The onset of symptoms rapidly shows and the animals’ motor abilities
gradually deteriorate.
L-BMAA treated animals present motor deficiencies together with ultrastructural alter-
ations in both the endoplasmic reticulum and the mitochondria [12, 13, 15]. Molecularly, alter-
ations of TAR DNA-binding protein 43 (TDP-43) and glycogen synthase kinase 3 (GSK-3),
two major markers of neurodegenerative diseases, are found. Accumulation of TDP-43 is one
of the main features of ALS and may have great relevance in the course of the disease [16].On
the other hand, GSK-3 can play a key role in the signalling cascades leading to neuronal degen-
eration and its levels are reported to be increased in ALS patients [15].
GSK-3 is a serine/threonine kinase originally identified as a regulator of glycogenmetabo-
lism that plays a pivotal role in numerous cellular functions, including cell cycle regulation, dif-
ferentiation and proliferation. Since the discovery of its involvement in the pathology of AD
[17], GSK-3 has been proposed as a new target enzyme for neurodegenerative diseases or brain
injury and, consequently, its inhibitors may represent new potential therapeutic drugs in
neurodegenerativemedicine [18].
GSK-3 is up-regulated in the brain and spinal cord of ALS patients [19] and the potential
role of its inhibitors have recently been described [20]. In the last two years, reported data has
supported the use of GSK-3 inhibitors as treatment for ALS and connected the post transla-
tional modifications found in TDP-43 with the upregulation of this kinase [21]. Efficacy of
GSK-3 inhibitors both on stem-cell-derivedmotor neurons [22] and SOD1 G93A transgenic
mice [23] have recently been reported, showing improved motor function and prolonged time
until symptom onset. However, the efficacy of GSK-3 inhibitors in the most prevalent sporadic
form of ALS remains yet to be studied.
Previous observations in animals treated with L-BMAA, such as the presence of fagosomes
and damagedmitochondria in spinal cord motoneurons have led us to think that autophagic
processes could be activated by this neurotoxin [13]. Zhang et al [24] describedautophagic alter-
ations in the SODmutant mousemodel, showing that there was a selective neurodegenerationof
motoneurons and demonstrating that activation of the autophagy pathway accelerates the course
of the disease and the neuropathological process. Autophagy has a key role in neurodegenerative
diseases [25], both as damage protective mechanism as well as neuronal cell death mechanism
GSK-3 Inhibitor in a Motor NeuronDiseaseModel
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[26]. ALS patients show an increment of autophagosomes in spinal cord motor neurons, that
have also been noticed on rodent models [27–29]. Alterations of autophagic pathways have been
extensively studied by several authors and have been proposed as a central mechanism of ALS
pathogenesis [30–32]. Therefore, autophagy could be the leading cause for disease development
in this model and its study could shed some light to the initial diseasemechanism of sALS.
Our research group has great experience on the design and synthesis of GSK-3 inhibitors
both as valuable pharmacological tools for biological studies and also as drug candidates [18,
33]. Among them, VP2.51 is a small heterocyclic compound that targets specificallyGSK-3
and has already proved to be effective in multiple sclerosis model [34].
The main objective of the present study is to test the potential of our toxin-basedmotor
neuron diseasemurine model as a pharmacological tool to be used in drug discovery, while
analysing the neuroprotective action of the selectedGSK-3 inhibitor. We have focused on the
evaluation of neurological symptoms and on the analysis of the autophagy processes in motor
neurons frommotor cortex and spinal cord. The results show the recovery of the animals
treated with VP2.51 immediately after finishing the L-BMAA treatment. Moreover, the treated
group showed a significant decrease in autophagy in motor cortex. Altogether, these results
represent the validation for the drug discovery process in a motor neuron diseasemouse model
with implications in the search for effective sALS treatments. To further confirm the involve-
ment of GSK-3 in the neuroprotection observed in the animals, a cellular experiment was per-
formed using a chemical genetic approach that utilizes chemically diverse GSK-3 inhibitors.
Materials andMethods
Chemical reagents were bought from Sigma-Aldrich (St. Louis, MO). Melting point was deter-
mined with a Mettler Toledo MP70 apparatus. 1H NMR spectra were obtained on the Bruker
AVANCE-300 spectrometer working at 300 MHz. Typical spectral parameters: spectral width
16 ppm, pulse width 9 μs (57°), data size 32 K. 13C NMR experiments were carried out on the
Bruker AVANCE-300 spectrometer operating at 75 MHz. The acquisition parameters: spectral
width 16 kHz, acquisition time 0.99 s, pulse width 9 μs (57°), data size 32 K. Chemical shifts are
reported in values (ppm) relative to internal Me4Si and J values are reported in Hz.
Analyses indicated by the symbols of the elements were within ± 0.4% of the theoretical val-
ues. 1-(5-Acetyl-4-methyl-1,3-thiazol-2-yl)-3-(4-methoxybenzyl)urea (VP2.51): 4-methoxy-
benzyl isocyanate (0.874 ml, 6.12 mmol) in 40 mL of DMF is mixed with 5-acetyl-2-amino-
4-methyl-1,3-thiazol (0.957 mg, 6.12 mmol) at 100°C for 14 h under nitrogen atmosphere and
then cooled down to room temperature. AcOEt (50 mL) and H2O (50 mL) are added to the
mixture. The organic extract is dried over anhydrous MgSO4 and evaporated under reduced
pressure to yield a yellow solid. The solid is recrystallized in a mixture of MeOH/H2O to afford
a white solid. Yield: 1.09 g, 56%. M.p. 196–197°C. 1H NMR (300 MHz, DMSO-d6): δ 10.85 (s,
1H, NH), 7.19 (d, J = 8.7 Hz, 2H, Ho), 7.01 (bs, 1H, NH), 6.86 (d, J = 8.7 Hz, 2H, Hm), 4.22 (d,
J = 5.9 Hz, 2H, (CH2-NH)), 3.69 (s, 3H, OMe), 2.47 (s, 3H, CH3-thiazole), 2.39 (s, 3H, CH3-
CO). 13C NMR (75 MHz, DMSO-d6): δ 190.2 (CO), 161.7 (NHCONH), 158.3 (Car-O), 153.2
(C2thiazole), 132.9 (C4thiazole), 131.1 (Ci), 128.7 (Co), 128.3 (C5thiazole), 113.8 (Cm), 113.6
(Cm), 55.1 (OMe), 42.5 (CH2-NH), 29.9 (CH3-CO), 18.1 (CH3-thiazole). HPLC: C18, 3.5 μM,
4.6 x 50 mm column, H2O/CH3CN 10:100 gradient in 5 min. Purity> 99%, r.t. = 4.08 min. MS
(ESI+): m/z 320 [M+1]. Elemental analysis of VP2.51 is reported on S1 Table.
Inhibition of GSK-3
Human recombinant GSK-3β was purchased fromMillipore (Millipore Iberica S.A.U.). The
prephosphorylated polypeptide substrate was purchased fromMillipore (Millipore Iberica S.A.
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U.). Kinase-Glo Luminescent Kinase Assay was obtained from Promega (Promega Biotech
Ibérica, SL). ATP and all other reagents were from Sigma-Aldrich (St. Louis,MO). Assay buffer
contained 50 mMHEPES (pH 7.5), 1 mM EDTA, 1 mM EGTA, and 15 mMmagnesium
acetate.
The method of Baki et al [35] was followed to analyse the inhibition of GSK-3β. Kinase-Glo
assays were performed in assay buffer using black 96-well plates. In a typical assay, 10 μl
(10 μM) of test compound (dissolved in dimethyl sulfoxide (DMSO) at 1 mM concentration
and diluted in advance in assay buffer to the desired concentration) and 10 μl (20 ng) of
enzyme were added to each well followed by 20 μl of assay buffer containing 25 μM substrate
and 1 μM ATP. The final DMSO concentration in the reactionmixture did not exceed 1%.
After 30 min incubation at 30°C the enzymatic reaction was stopped with 40 μl of Kinase-Glo
reagent. Glo-type luminescencewas recorded after 10 min using a FLUOstar Optima (BMG
LabtechnologiesGmbH, Offenburg, Germany) multimode reader. The activity is proportional
to the difference of the total and consumed ATP. The inhibitory activities were calculated on
the basis of maximal activitiesmeasured in the absence of inhibitor. The IC50 was defined as
the concentration of each compound that reduces by 50% the enzymatic activity. To investigate
the inhibitorymechanism of VP2.51 on GSK-3β, a kinetic study varying both ATP (from 1 to
50 μM) and VP.251 (from 0.5 to 1 μM) concentrations were performed using the ADP-Glo
Kinase Assay [36].
To study the type of enzymatic inhibition for the compounds, measurements after several
times of incubation of the enzyme with the inhibitor VP2.51 were performed. A reversible
inhibitor does not increase the inhibition of the enzyme with the time of incubation, while an
irreversible inhibitor increases the inhibition percentage as the time of incubation with the
enzyme increases.
In vitro parallel artificialmembrane permeabilityassay (PAMPA)
Prediction of the brain penetration was evaluated using a parallel artificialmembrane perme-
ability assay (PAMPA). Ten commercial drugs, phosphate buffer saline solution at pH 7.4
(PBS), DMSO and dodecanewere purchased from Sigma, Across organics, Aldrich and Fluka.
The porcine polar brain lipid (PBL) (catalog no. 141101) was from Avanti Polar Lipids. The
donor plate was a 96-well filtrate plate (Multiscreen IP Sterile Plate PDVF membrane, pore size
is 0.45 μM, catalog no. MAIPS4510) and the acceptor plate was an indented 96-well plate (Mul-
tiscreen, catalog no. MAMCS9610) both fromMillipore. Filter PDVF membrane units (diame-
ter 30 mm, pore size 0.45 μm) from Symta were used to filter the samples. A 96-well plate UV
reader (Thermoscientific,Multiskan spectrum)was used for the UVmeasurements. Test com-
pounds were dissolved in DMSO (250 μL). 25 μL of this compound stock solution was taken
and 225 μL of DMSO and 4750 μL of PBS pH 7.4 buffer were added to reach 5% of DMSO con-
centration in the experiment. These solutions were filtered. The acceptor 96-well microplate
was filledwith 180 μL of PBS:DMSO (95:5). The donor 96-well plate was coated with 4 μL of
porcine brain lipid in dodecane (20 mg mL-1) and after 5 minutes, 180 μL of each compound
solution was added. 1–2 mg of VP2.51 was dissolved in 250 μL of DMSO and 4750 μL of PBS
pH 7.4 buffer, filtered and then added to the donor 96-well plate. Then the donor plate was
carefully put on the acceptor plate to form a “sandwich”, which was left undisturbed for 4 h at
25°C. During this time the compounds diffused from the donor plate through the brain lipid
membrane into the acceptor plate. After incubation, the donor plate was removed. The concen-
tration of VP2.51 and commercial drugs in the acceptor and the donor wells was determined
by UV plate reader. Every sample was analyzed at three to five wavelengths, in 3 wells and in
three independent runs. Results are given as the mean [standard deviation (SD)] and the
GSK-3 Inhibitor in a Motor NeuronDiseaseModel
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average of the three runs is reported. Validation was made comparing the reported permeabili-
ties values of commercial drugs with the experimental data obtained employing this methodol-
ogy. A good correlation between experimental-describedvalues was obtained Pe (exptl) =
1.0123 (bibl) + 0.1038 (R2 = 0.975) (S1 Fig). From this equation and following the pattern
established in the literature for BBB permeation prediction [37] we could classify compounds
as CNS + when they present a permeability> 4.15 x 10−6 cm s-1 (S2 Table).
Cell culture
SH-SY5Y cells on a 96 well plate ere incubated with L-BMAA (10 mM) with or without inhibi-
tors (10 μM). A control experiment was set at the same time without L-BMAA or inhibitors.
After 24 h a MTTwas performed to determine cell viability using known procedures in the lit-
erature. [38] Experiment was performed in triplicate.
Animals
Assays were carried out using male rats of Rattus norvegicus, albino variety, Wistar strain, that
were supplied by Harlan Interfauna Ibérica S.A. (Barcelona, Spain). Animals were kept at con-
stant temperature (21 ± 1°C) on a reversed light/dark cycle with diets and water ad libitum
(A04 commercial rodent diet, Panlab, Barcelona, Spain). The trials were approved by the Ethics
Committee for Animal Experimentation of the Universidad Complutense deMadrid according
to EU Directive 2010/63/EU for animal experiments. Animal’s health was monitored by weight
control. No animals were severely ill or died at any time prior to the experimental endpoint.
Animals were sacrificed at the established time point under general anaesthesia with isoflurane
(ISOFLO1, Abbott Laboratories, Abbott Park, IL, USA).
L-BMAA treatment
At weaning time (postnatal day 21) animals, with a weight between 45 and 55 g, were intraperi-
toneally (i.p.) injected with 300 mg/kg of L-BMAA (L-BMAA hydrochloride, Sigma-Aldrich,
Ref. B107), during 5 consecutive days. The injected solution was composed by 50 mg of
L-BMAA dissolved in 500 μl of PBS (0.1 mg / μl). Controls were injected with a similar volume
of PBS, according to their weight.
VP2.51 treatment
VP2.51 was dissolved in a stock solution of DMSO (dimethyl sulfoxide, Sigma) at 100 mg/mL.
This stock was used to prepare a final solution of 1 mg/mL in PBS with 5% DMSO and 5%
Tween1 80 (Sigma). Rats were injected i.p. 2.5 mg/Kg beginning at two different times: on the
first day after treatment with L-BMAA (PT1) and on day post-treatment 30 (PT30). Injection
treatment was performed for 15 consecutive days. Two control groups that had not received
the L-BMAA treatment were injected with VP2.51 at the same scheduled times of the L-BMAA
and VP2.51 treated groups.
In summary, 6 different groups of 12 animals each were used: Control (only PBS injected),
L-BMAA, L-BMAA+VP2.51 PT1, VP2.51 PT1, L-BMAA+VP2.51 PT30, VP2.51 PT30. Weight
monitoring was performed every day during 100 days. After this time the animals were
sacrificed.
Neurological evaluation
The neurological tests were carried out blindly as described by de Munck et al [13], once a
week during 100 days. Briefly, the neurological assess was carried out with three different tests:
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ambulation, tail suspension test and strength test. The three approaches of the assessment had
not an equal contribution to the final neurological evaluation: the tail suspension test repre-
sents 70% of the total assessment, and the other two tests were used to fine tune the details of
the value with an importance of 15% each. During the ambulation both postural control and
the way the hind limbs were leant during motion was observed. In the tail suspension test, the
rat was suspended by the tail at 10 cm over the surface. The ability to keep the hind limbs in
the normal neutral position adopted by rodents in such situation, i.e., describing a “T” was
evaluated, together with the stiffness of the limbs and the inter-limb coordination during kick-
ing. The strength test and was carried out setting down the rats on a flat surface, both forelegs
and hind limbs on it, while pulling the tail softly to the opposite direction of animal usual move
course. The ability the rats had to drag and offer resistance, assessing their faculty to kept hind
limbs under the body without spreading their legs away from it was observed.The neurological
evaluation was established in a scale comprised between 0 and 10, where 0 is the evaluation
given to animals which are not symptomatic, control animals, and 10 belongs to a state of total
functional loss of the hindlimbs and postural control. Three videos showing the tests per-
formed for the neurological evaluation of control (S1 Movie), L-BMAA (S2 Movie) and
L-BMAA +VP2.51 (PT1) (S3 Movie) rats can be found in the SI.
Analysis of LC3-II and P-mTOR
The animals were sacrificedunder general anaesthesia with isoflurane (ISOFLO1, Abbott
Laboratories, Abbott Park, IL, USA), 5% O2. The entire brain and the lumbar spinal cord were
rapidly removed and stored at -80°C.
To analyse LC3-II and P-mTOR by western-blot, 100 mg of motor cortex and lumbar spinal
cord of each animal were homogenized in a RIPA buffer: 50 mM Tris–HCl pH 7.4, 50 mM
NaCl, Nonidet P-40 1%, 1 mM EDTA, 1 mM PMSF, 1 mg/mL aprotinin, 1 mg/mg leupeptin, 1
mg/mL pepstatin, at a rate of 10 mL of buffer per 1 mg of tissue. The mixture was sonicated for
2 min with 2 s pulses of sonication and 2 s off at amplitude of 40%. Once the samples were
homogenized, the evaluation and protein electrophoresis was performed. The protocol was
adapted from Zhang et al [24] as described in Muñoz-Sáez et al [14].
Before the electrophoresis, the protein concentrations of all samples were determined by
Bradford assay (Sigma–Aldrich Inc., St. Louis, MO, USA; Bradford, 1976).
Electrophoresis for protein separation was performedby SDS-PAGE. In all cases, the concen-
trating gel contained 6% polyacrylamide.Regarding LC3-II, the percentage of polyacrylamidewas
12% for the separating gel and for P-mTOR an 8% polyacrylamide separating gel was used. Subse-
quently, proteins from the gels were transferred to a nitrocellulosemembrane (AmershamTM
HybondTM–ECL) in a wet system at 10 V o/n and 4°C.Membranes were incubated with follow-
ing primary antibodies: a rabbit polyclonal anti-tubulin β-III (Novus Biologicals, Littleton, CO,
USA), a rabbit polyclonal anti-LC3-II (Novus Biologicals, Littleton, CO, USA) and rabbit poly-
clonal anti-mTOR (Phospho-Ser2448) (Novus Biologicals, Littleton, CO, USA). As a secondary
antibody, we applied Donkey anti-rabbit IgG-Fc Horseradish Peroxidase (HRP) (Bethyl Laborato-
ries,Montgomery, TX,USA). All the antibodies were used according to the manufacturers’ speci-
fications. Proteins were detected by enhanced chemiluminescence.Digital images were acquired
using a Fujifilm Intelligent Darkbox II (Fuji Systems USA, Stamford, CT) and the image process-
ing for quantification was conductedwith free image processing software Image J.
Statistical analysis
Results are presented as means ± SEM in graphics. Data were adjusted to the most suitable
regression model, weight by Boltzmann sigmoidal regression and neurological evaluation, after
GSK-3 Inhibitor in a Motor NeuronDiseaseModel
PLOSONE | DOI:10.1371/journal.pone.0162723 September 15, 2016 6 / 16
normalisation, by linear regression, and then analysed by F-test. Data from each biochemical
experiment was analysed separately and treated by ANOVA including a Bonferroni post-test.
Student’s t-test was also used to compare the samples. Experiments were repeated three times
with triplicate samples for each experiment. The data were analysed using Graph Pad Prism
v5.03 software. Values of p 0.05 were considered statistically significant.
Results
Characterizationof VP2.51 as a brain permeableGSK-3 inhibitor
Several authors have recently highlighted the potential of GSK-3 inhibitors to restore or reduce
damage to the central nervous system caused by neurodegenerative diseases or other factors
[39]. Genetic or pharmacological inhibition of GSK-3 protects neurons from a wide range of
environmental stresses including hypoxia and amyloid toxicity, which may be relevant for the
treatment of stroke or diseases such as Alzheimer’s disease [40]. The involvement of GSK-3 in
ALS has recently been reviewed in various experimental studies where GSK-3 inhibitors were
used in animal and cell models [41], [42]. Clinical studies have also shown the potential thera-
peutic role of these molecules [20].
To assess the therapeutic potential of GSK-3 inhibitors in a motor neuron diseasemurine
model the 1,3-thiazole derivative named VP2.51 was selected. This heterocyclicmolecule was
designed based on the crystal structure of the complex 1Q5K by modification and elimination
of toxicophores residues such the nitro functional group changed by chemical groups that
allow switching from reversible to irreversible inhibitors [43], [44].
Its GSK-3 inhibitory activity has an in vitro IC50 value of 0.62 ± 0.15 μM on human recom-
binant enzyme, and time dependent experiments showed a reversible inhibition (Fig 1A).
Kinetic experiments were also performed showing that VP2.51 competes in vitro with ATP for
the GSK-3 binding site (Fig 1B). As ATP-competitive inhibitors may have selectivity in vivo
complications, a kinase profiling over a panel of fifty different human kinases was done using a
fixed concentration of VP2.51 at 10 μM. VP2.51 shows a high selectivity profile targeting only
both isoforms of GSK-3, α and β, and with less potency, casein kinase-1δ (CK-1δ) (Fig 1C).
Further determination of the IC50 value for CK-1δ inhibition following a describedprotocol,
showed a value of 7.28 ± 0.87 μM, tenfold greater than the corresponding to GSK-3 inhibition.
It is worth mentioning that CK-1δ inhibitors have recently been reported as new drug candi-
dates for ALS therapy based on their ability to reduce TDP-43 hyperphosphorylation [44].
Finally, the ability to cross the blood-brain barrier (BBB) was determined. This is a key fea-
ture for considering this compound as a drug candidate for the potential treatment of central
nervous system diseases. VP2.51 permeability through the BBB was evaluated by a parallel arti-
ficial membrane permeability assay (PAMPA) using porcine brain membrane lipid and ten
commercial drugs following the methodologydescribedby Di et al. [37] Its effective permeabil-
ity was 7.6 ± 0.4 x 10−6 cm/s (S1 Fig and S2 Table), which is compatible with a good brain pene-
tration. Lastly, it is worth mentioning that VP2.51 is a weak or partial inhibitor of the
cytochromes P450 family [45] which points to the safe in vivo profile of this compound.
L-BMAA and VP2.51 treatment
At weaning time, animals were intraperitoneally (i.p.) injectedwith 300 mg/kg of L-BMAA,
during 5 consecutive days. After neurotoxin treatment, VP2.51 was injected i.p. 2.5 mg/Kg
beginning at two different times: on the first day after treatment with L-BMAA (PT1) and on
day post-treatment 30 (PT30). Injection treatment was performed for 15 consecutive days.
Two control groups that had not received the L-BMAA treatment were injectedwith VP2.51 at
the same scheduled times of the L-BMAA and VP2.51 treated groups.
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Collectively 6 different groups were used: control (only PBS injected), L-BMAA, L-BMAA+
VP2.51 PT1, VP2.51 PT1, L-BMAA+VP2.51 PT30, VP2.51 PT30 and they were observeddur-
ing 100 days.
Evaluation of disease progression on motor neuron diseasemodel
Weight progression, neurological evaluation and analysis of autophagy were performed blindly
to assess the disease progression on the rats.
Weight progression. Statistical analysis revealed no significant differences between
groups, indicating that VP2.51 and L-BMAA do not affect physical development of rats neither
Fig 1. Biological activityof VP2.51 onGSK-3 and other protein kinases.A) Time-dependent GSK-3 inhibition
of VP2.51 at 1 and 2 μM. B) Kinetic GSK-3 inhibition data determined for VP2.51. ATP concentrations in the
reactionmixture varied from 1 to 50 μM. Compound concentrations used are depicted in the plot, and the
concentration of GS-2 was kept constant at 12.5 μM. Each point is the mean of two different experiments, each one
analyzed in duplicate. C) Kinase profiling of VP2.51 on human recombinant kinases. The percentage (%) of kinase
activity after the treatmentwith a fixed concentration (10 μM) of the compound is shown.
doi:10.1371/journal.pone.0162723.g001
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alone or co-administered (Fig 2). These results show that VP2.51 alone does not cause deleteri-
ous physical side effects in animals.
Neurological evaluation. A scale comprised between zero and 10 points, where zero is the
evaluation given to animals which are not symptomatic, control animals, and 10 score belongs
to a state of total functional loss of the hind limbs and postural control was used to evaluate
neurological abnormalities.
L-BMAA treated animals reached a value of 7 points in the neurological evaluation score.
The animals show a major impediment to maintain a correct posture while the tail suspension
test was carried out. In addition, they suffer from a lateralized ambulation, and have problems
completing turns on the march. Further, the animals kept the legs relaxed and pitched towards
the ventral side. Concerning the strength test, the treated rats’ hind limbs protruded from the ver-
tical projection of the body on the table while they sought to counteract the pressure on their tails
(S2Movie) [13]. The group treated with VP2.51 from day 1 after treatment with L-BMAA
(L-BMAA + VP2.51 PT1) (S3Movie) presented highly significant differences in the evolution of
the neurological evaluation from the group treated only with L-BMAA (F = 89.34, p<0.0001)
(Fig 3). These animals markedly improved their neurological evaluation, almost reaching levels
of control animals in three months. These animals maintain a correct posture at the tail suspen-
sion test and show neither lateralized ambulation nor strength loss. However, animals treated
with VP2.51 from day 30 post-treatment after injections with L-BMAA (L-BMAA + VP2.51
PT30), did not show significant differences with the animals treated with L-BMAA.
The control group (S1Movie) and the groups treated exclusively with VP2.51 (PT1 and PT30)
had a neurological evaluation score of zero and are not shown in Fig 2. The results obtained from
the neurological evaluation confirm that VP2.51 does not promote either neurological pathologies
or observable toxicities and clearly has a neuroprotective effect when administered during two
weeks from the first day after treatment with L-BMAA (PT1). Neurological symptoms of treated
animals improved markedly to almost the level of controls within threemonths.
Analysis of Autophagy. As VP2.51 prevents the neurological effects of L-BMAA in neuro-
logical evaluation of animals when administered from day PT1, we analyzed the possible effects
of this GSK-3 inhibitor on autophagy caused by L-BMAA in the motor cortex and lumbar spi-
nal cord. LC3-II is used as a standard marker of autophagy levels in tissues [46], and was ana-
lysed by Western blotting. Our results indicate that animals treated with L-BMAA present
both LC3-II and P-mTOR levels significantly higher than control animals in the motor cortex
(LC3-II: t = 5.969; p = 0.027; P-mTOR: t = 5.889, p = 0.0042) (Fig 3A) and the lumbar spinal
cord (LC3-II: t = 46.85; p = 0.0005; P-mTOR: t = 3.257, p = 0.031) (Fig 3B). ANOVA test
showed statistical differences between the different groups regarding LC3-II (F = 5.56,
p = 0.0234) and P-mTOR (F = 37.22, p<0.0001) in the motor cortex.Moreover, animals
treated with L-BMAA+VP2.51 at PT1 presented both LC3-II levels (t = 3.547, p<0.05) and P-
mTOR levels (t = 7.223, p<0.001) significantly lower than animals treated with L-BMAA.
LC3-II levels in the lumbar spinal cord offered significant differences between groups
(F = 13.12, p = 0.0019), being higher in animals treated with L-BMAA and lower in controls
and L-BMAA +VP2.51 to PT1 treated animals. (t = 5.083, p<0.01). Animals treated with
L-BMAA + VP2.51 to PT1 show a lower non-significant P-mTOR level in this tissue compared
with L-BMAA treated groups.
Cell culture. Mechanistically and structurally diverse GSK-3 inhibitors were tested in a
cellular model of L-BMAA to study whether GSK-3 inhibition was implicated in neuroprotec-
tion at L-BMAA damage, using a forward chemical genetic approach. VP2.51 and INH-38 [43]
are ATP-competitive inhibitors of GSK-3, ITDZ 55 [47] is a substrate competitive inhibitor
and VP0.7[48] is an allosteric inhibitor that does not compete with the ATP nor the substrate
in its GSK-3 inhibition and was proposed to bind to a pocket at the C-lobe of the enzyme. Cells
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Fig 2. Weight progression and neurological evaluation.A) Evolution of rat weight of different treatment groups (12 animals in each group):
control, L-BMAA (300mg/kg/day during 5 consecutive days treated at weaning), VP2.51 (2,5mg/kg during 15 days) with a group treated at PT1
and another at PT30, L-BMAA (with the same treatment as the group of L-BMAA) + VP2.51 (with the same treatment groups VP2.51) with a
group treated at PT1 and another at PT30. B). Evolution of neurological evaluation in the treatment assay with VP2.51 (12 animals in each
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were incubated with L-BMAA together with or without inhibitors for 24 h and cell viability
was determined. Fig 4 shows how GSK-3 inhibitors protect cells from L-BMAA damage,
engaging GSK-3 as the target for the observed effect.
Discussion
The finding of the neurotoxic amino acid L-BMAA in Alzheimer’s disease and ALS patients
has led some authors to propose the hypothesis that L-BMAA accumulation could be related to
the development of several neurodegenerative diseases [49]. L-BMAA is an unnatural amino
acid that can become part of protein chains. Once incorporated into the chain, proteins can no
group). The control group and the groups treated exclusively with VP2.51 (at PT1 and PT30) are not shown because its assessment coincides
with the horizontal axis. The time when the inhibitor is added is indicatedwith arrows.
doi:10.1371/journal.pone.0162723.g002
Fig 3. Autophagy evaluation inmotor cortex and lumbatr spinal cord A) Analysis of LC3-II and P-mTOR by western-blot in the motor cortex of
control and treated animals. Proteinswere detected by Western blotting using β-tubulin for calibration of sample loading. The protein bands were
quantified by ImageMultigauge v3.0 software. Immunoblots are representative of one of three experimentswith similar results. These results were
quantitated in arbitraryunits and were represented in the accompanying graphs as mean ± SEM. *, ** Indicate differences of p-value <0.05 <0.01 with
the control group, respectively. #, ### indicate differences of p-value <0.05 <0.001with the group of animals treatedwith L-BMAA, respectively. B)
Analysis of LC3-II and P-mTOR by western-blot in the lumbar spinal cord of control and treated animals. Proteinswere detected by Western blotting
using β-tubulin for calibration of sample loading. The protein bands were quantified by ImageMultigauge v3.0 software. Immunoblots are
representative of one of three experimentswith similar results. These results were quantitated in arbitraryunits and were represented in the
accompanying graphs as mean ± SEM. *, *** Indicate differences of p-value <0.05 <0.001with the control group, respectively. ## Indicate differences
of p-value <0.01 with the group of animals treatedwith L-BMAA.
doi:10.1371/journal.pone.0162723.g003
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longer fold properly. Accumulation of L-BMAA in the proteins of nerve cells, which need to
last a lifetime, would provide a mechanism of how the toxin could have effects in later times.
Neurons accumulate damaged proteins over time, and once they reach a critical level, it causes
the cell to undergo apoptosis. In this regard, studies in our laboratory have shown that
L-BMAA treated rats would be a good experimentalmodel of a motor neuron diseasemimick-
ing some aspects of sALS [13] and we have applied it to study the therapeutic action of a GSK-
3 inhibitor for the treatment of this neurodegenerative disorder.
The results obtained from the neurological evaluation could be considered as clinically rele-
vant since the administration of a drug prior to symptoms onset allows a protective therapy. In
this case, the GSK-3 inhibitor used has shown neuroprotective activity against neurotoxicity
caused by L-BMAA. As the compound administration starts after the induction of ALS symp-
toms by 5 days treatment with L-BMAA, the efficacy shown with VP2.51 may be translated
into a potential clinical treatment for early diagnosed patients: as soon as the first neurological
sign is detected in a patient or in case a genetic analysis identified a familiar ALS, the treatment
with VP2.51 or any other GSK-3 inhibitor may be recommended. Results also show that the
earlier the disease is diagnosed, the better response to the treatment is to be expected.
Results from the autophagy analysis show that L-BMAA causes activation of autophagic
processes and are in agreement with those obtained by Hetz et al [50] in spinal cord samples of
sALS and fALS patients, where they observed a marked induction of LC3-II. The importance
of apoptosis in diseases characterized by proteinopathies, such as ALS has been emphasized
recently [51, 52]. Thanks to research in this direction it has been established that high levels of
protein aggregates can cause dysfunction of the unfolded protein response [53], and subse-
quent compensatory activation of autophagy [54].
In the present work it is shown how VP2.51 prevents the activation of autophagic processes
in L-BMAA treated animals when it is administered from day 1 post treatment. In motor cor-
tex, VP2.51 causes the decrease of the marker protein autophagy LC3-II and the concomitant
decrease of P-mTOR respect to L-BMAA treated group, reaching levels similar to those
obtained in the control group. In lumbar spinal cord, VP2.51 administration to PT1 after
Fig 4. Neuroprotectionof cellular L-BMAAmodel by diverseGSK-3 inhibitors.A) Diverse GSK-3 inhibitors selected showing their inhibition kind. B)
Cell viabilitymeasured in the experiment with or without inhibitors.
doi:10.1371/journal.pone.0162723.g004
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treatment with L-BMAA also seems to prevent activation of autophagic processes, given the
reduction in LC3-II levels found. Although in this case a significant decrease in P-mTOR levels
respect to the group treated only with L-BMAA was not shown, a tendency to decrease can be
noticed. Therefore, VP2.51 treatment prevents activation of autophagy produced by L-BMAA
in the motor cortex and the lumbar spinal cord, two of the main motor control centres affected
by ALS.
Finally, a cellular experiment was performedwith diverse GSK-3 inhibitors to study target
engagement in neuroprotection at the event of L-BMAA damage. Using a forward chemical
genetic approach mechanistically and structurally varied GSK-3 inhibitors showed an
increased cell viability when coincubated with L-BMAA, thus confirming the involvement of
GSK-3 as a key player of cell protection in this model.
Conclusions
In the present work the pharmacological utility of a motor neuron diseasemurinemodel based
on the L-BMAA neurotoxicity was evaluated showing that treatment with VP2.51, a selective
GSK-3 inhibitor, from the earliest moments of L-BMAA action, prevents the onset of motor
symptoms produced by this neurotoxic amino acid. In addition, this neuroprotective effect of
VP2.51 is associated to inhibition of autophagy in motor cortex and lumbar spinal cord. We
show how autophagy may be playing a key role in disease progression and how its suppression
may be fundamental to reduce or reverse disease pathology. The neuroprotective effect of VP2.51
this murinemodel is a promising finding and requires further study in order to clarify its action.
An additional cellular experiment was performedwith mechanistically and structurally distinct
GSK-3 inhibitors showing the involvement of the target in this motor neuuron diseasemodel
induced by L-BMAA. GSK-3 inhibitors and specificallyVP2.51 emerge as a potential therapeutic
option for the early diagnosed treatment of motor neuron diseases like ALS.
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